Total | Group 1 (early adopters) | Group 2 (intermediate) | Group 3 (late adopters) | P value | |
Antihypertensive drugs, % | 55.8 | 45.4 | 49.5 | 59.8 | <0.001 |
ACEi, % | 27.9 | 21.2 | 24.7 | 30.0 | <0.001 |
ARB, % | 19.2 | 16.8 | 17.7 | 20.1 | 0.083 |
Beta-blockers, % | 31.4 | 19.6 | 25.8 | 35.1 | <0.001 |
Diuretics, % | 25.5 | 17.8 | 21.9 | 27.9 | <0.001 |
Calcium antagonists, % | 17.9 | 12.5 | 15.4 | 19.5 | <0.001 |
Lipid-lowering agents, % | 42.1 | 28.3 | 36.4 | 46.0 | <0.001 |
Statins, % | 39.9 | 26.1 | 34.2 | 43.8 | <0.001 |
Ezetimibe, % | 2.9 | 1.4 | 2.1 | 3.4 | 0.004 |
Other non-statin LLT, % | 2.9 | 3.4 | 2.8 | 2.9 | 0.803 |
Antiplatelet, anticoagulant drugs, % | 22.1 | 11.7 | 17.4 | 25.3 | <0.001 |
Platelet aggregation inhibitors, % | 19.0 | 11.7 | 15.1 | 21.5 | <0.001 |
Oral anticoagulants, % | 5.1 | 0.0 | 4.2 | 5.8 | <0.001 |
Glucose-lowering therapies, % | 87.7 | 80.2 | 83.1 | 90.6 | <0.001 |
Insulin, % | 45.1 | 34.3 | 37.2 | 49.9 | <0.001 |
Metformin, % | 65.4 | 60.8 | 59.7 | 68.6 | <0.001 |
Acarbose, % | 0.6 | 1.0 | 0.9 | 0.4 | 0.157 |
Sulfonylurea, % | 5.8 | 9.3 | 6.8 | 5.0 | <0.001 |
DPP-4 inhibitors, % | 31.2 | 25.2 | 31.1 | 31.8 | 0.071 |
GLP-1 agonists, % | 13.2 | 12.1 | 12.2 | 13.9 | 0.317 |
SGLT2 inhibitors other than empagliflozin, % | 2.9 | 7.9 | 2.3 | 2.7 | <0.001 |
ACEi, ACE inhibitor; ARB, angiotensin-receptor blocker; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; LLT, lipid-lowering therapy; SGLT-2, sodium-glucose transport protein-2.